Testimonials to the power of the µTexture diagnostic from Key Opinion Leaders & Industry

Guy Umberto Poloni, PhD. 

Siemens Medical Solutions USA, Director MR R&D Collaborations Siemens Healthineers

"Siemens’ strategy towards improving quantitative MRI will impact not only the diagnostic accuracy and specificity of MRI, but also therapeutic outcomes by providing MR metrics that can monitor therapeutic response. Siemens sees the development of technologies such as μTexture in clear alignment with its product strategy, and the possibility of offering the proposed technologies to our 7T customers would be an opportunity to enhance our product performance. We see the future development of this technology could have a very major impact in the field of neuroscience and clinical brain imaging."

Arthur Toga, Ph.D.

Director of the Laboratory of Neuroimaging and the Mark and Mary Stevens Institute of Neuroimaging and Informatics at the Keck School of Medicine; USC Provost Professor of Ophthalmology, Neurology, Psychiatry and The Behavioral Sciences, Radiology and Engineering; Ghada Irani Chair in Neuroscience

“If the potential of the MR-based μTexture diagnostic technology is realized, it will be the only non-invasive, direct measure of tissue texture available, enabling early stage diagnosis and monitoring in many heretofore inaccessible brain pathologies, thereby greatly improving outcomes.”

Garry Gold, M.D. , M.S.

Vice Chair for Research & Administration, Stanford University Department of Radiology; Professor of Radiology (Musculoskeletal Imaging), Stanford University; Fellow, American Institute for Medical and Biological Engineering (AIMBE) 2016; President, International Society for Magnetic Resonance in Medicine (ISMRM) 2016-2017

 “As data acquisition takes under a minute, it doesn’t add to the cost of a scan, yet provides high value diagnostic data—answering the health care mandate for value-based care. Indeed, MR·based measurements of the fine tissue textures pertinent to pathology, down to the tens of microns range, is by definition a game-changer in diagnostics.”

John V. Crues, M.D., M.S.

Founder and Medical Director,  RadNet, Inc. (290+ outpatient radiology centers in the US); past president of the ISMRM  

“If current research proves the value of µTexture in diagnostic medicine, then I would be very eager to see it implemented as a diagnostic study on RadNet’s MR scanners. The extremely low cost of implementation, combined with the almost negligible input in time and effort for data acquisition, make it a win-win for clinical practice.”

Scott T. Grafton M.D.

Head of the UCSB Brain Imaging Center; Bedrosian-Coyne Presidential Chair in Neuroscience; Professor Psychological and Brain Sciences UCSB; Co-director Institute for Collaborative Biotechnologies (ICB)

“Early diagnosis is going to be essential for disease modifying agents to become effective in neurologic disorders.  The high information content of µTexture’s data output, combined with the biomarker definition capability afforded by machine learning, would yield a powerful diagnostical tool.”

© 2019 bioProtonics, Inc.